Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...

Innophore will launch the CavitOmiX AI tool to screen for new drugs, predict side effects, and repurpose existing molecules.

A Chinese pharmaceutical company expects to hire up to 500 employees for the first phase of its new campus in northern ...

Shares of WuXi group companies jumped Monday after U.S. President-elect Trump promised to save TikTok and held a call with his counterpart in China, sparking tentative hopes that some areas of ...

Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. | The deal includes facilities in ...

Legend Biotech Corporation (NASDAQ:LEGN) has been making waves in the biotechnology sector with its flagship product, ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.